Company intelligence / Profile preview
Lipocine Inc
Salt Lake City, Utah, United Stateslipocine.com ↗
- Ownership
- Public · LPCN
- Development stage
- Other
01
Overview
Lipocine has one FDA-approved product (TLANDO) for testosterone replacement therapy. Their lead candidate LPCN 1144 has completed Phase 2 clinical studies for NASH treatment. Other pipeline products are in various stages of development.
- Therapeutic areas
- GastroenterologyPsychiatryMen's HealthEndocrinologyWomen's HealthNeurology
- Modalities
- Oral prodrugssmall molecules
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Verity Pharmaceuticals (commercialization of TLANDO in the US)Antares Pharma Inc (previous licensing agreement for TLANDO)Gordon Silver Limited
04
Financials
- Market cap
- $12.6M
- Total revenue
- $2M
- Enterprise value
- $-8.8M
Beyond the preview
Go deeper on Lipocine Inc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lipocine Inc.